Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
Sthanu Subramanian, Pediatrician, shared a post on X about a recent article by Noel C. Chan et al. published in Arteriosclerosis, Thrombosis, and Vascular Biology, adding:
“Dabigatran and Mechanical heart valves.
Dabigatran (Pradaxa) is contraindicated for mechanical heart valves because it is significantly less effective at preventing blood clots on artificial valves and carries a higher risk of major bleeding compared to traditional treatments like Warfarin.
The danger of using dabigatran in these patients was proven by the RE-ALIGN Trial, which was stopped early due to severe safety risks.
The specific reasons for this include:
1. Higher Rates of Valve Thrombosis:
Dabigatran only targets one specific clotting factor (thrombin).
Mechanical valves are highly prone to clot formation, and warfarin’s broader mechanism of action is much more effective at preventing clots from building up on the artificial material.
2. Increased Risk of Strokes:
Because dabigatran fails to adequately prevent clots from forming on the valves, users experienced more strokes and systemic embolisms.
3. Excessive Bleeding:
The drug also led to a significantly higher rate of major bleeding events, including dangerous bleeding in the pericardial space surrounding the heart.
4. Absorption Issues:
Dabigatran has very low oral bioavailability and can cause topical anticoagulant effects in the gastrointestinal tract, contributing to higher bleeding risks.
Mechanisms of mechanical heart valve thrombosis and the differential effects of anticoagulants on thrombin generation.”
Title: Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective?
Authors: Noel C. Chan, Jeffrey I. Weitz, John W. Eikelboom
Other posts featuring Sthanu Subramanian on Hemostasis Today.
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
-
Jun 27, 2026, 18:17Michiel Coppens: A Hemostasis Laboratory – One of the Cornerstones of Our Hemophilia Mission
-
Jun 27, 2026, 15:50Muhammet Özbilen: The Skin as an Emerging Regulator of Iron Homeostasis
-
Jun 27, 2026, 15:07Anteneh Berhane: Supporting Healthier Pregnancies Through Early Nutrition
-
Jun 27, 2026, 14:35Mobina Nakhaei: Why Alloantibodies Develop Despite ABO/Rh Matching in Thalassemia
-
Jun 27, 2026, 14:01Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins
-
Jun 27, 2026, 14:01Francesca Palandri: Highlighting Innovation in Rare Disease Care at EHA 2026